Soon-to-be public biopharma firm moves to Fort Collins, submits new drug application for COVID treatment

Dan Mika

FORT COLLINS — A biopharmaceutical firm that intends to go public in the next month or so is seeking clearance to start trials for a possible treatment to inhibit the COVID-19 virus from replicating itself in an infected person, its first major move since moving to Fort Collins.

In a statement, Cytocom Inc. said it submitted an Investigational New Drug Application to the U.S. Food and Drug Administration for its drug candidate CYTO-205, which is thought to help patient immune systems maintain the correct levels of cytokine release when fighting infection or illness.

The company said that the drug candidate has…